Contact Us
Welcome To Lupvindol

Pioneering Pain Management

Lupvindol Bioscience is a leading innovator in the treatment of autoimmune and inflammatory conditions affecting both humans and animals. The company is advancing FDA-approved clinical trials for fixed-dose combinations of cannabidiol (CBD) and corticosteroids, aiming to revolutionize therapeutic approaches in this field.

Our mission is to achieve super-additive efficacy, where the combined treatments not only enhance therapeutic outcomes but also significantly reduce side effects. This aligns with our commitment to improving patient care while minimizing risks associated with conventional therapies.

Follow Our Journey
About us

Revolutionizing Steroid-CBD Therapy

Contact Us

Lupvindol Biosciences is a dynamic, cutting-edge company with robust intellectual property (IP) for combining the benefits of two existing FDA-approved pharmaceutical drugs— corticosteroids and CBD—into a fixed-dose combination formulation. This innovation aims to replace traditional inflammatory and auto immune regimens plagued by dose-limiting side effects, especially with prolonged use. Our data suggest enhanced efficacy and safety compared to steroids alone, at much lower doses.

The Problem

Maximizing Steroid Benefits While Minimizing Side Effects

Corticosteroids are powerful tools in managing inflammatory pain and autoimmune conditions but come with a significant risk of side effects, particularly with long-term or high-dose use. These side effects can include osteoporosis, muscle atrophy, high blood pressure, diabetes, or psychiatric disturbances such as mood swings or psychosis. Physical changes like “moon face,” fat redistribution, or skin thinning are also common, alongside vision problems such as cataracts or glaucoma.

The Solutions

Patent Combination Therapy

Lupvindol’s robust patent portfolio underpins the development of formulations combining CBD and corticosteroids in optimized ratios. CBD’s established potential as a steroid-sparing agent allows Lupvindol to address the adverse effects associated with long-term or high-dose steroid use, offering a safer alternative for managing inflammatory and autoimmune conditions.

A Vision for Leadership

Our Journey

Our groundbreaking approach is poised to seize market leadership in the lucrative animal treatment sector within two years, setting the stage for extensive data collection to support prompt human Phase III clinical development.
0 +
Patents Secured
0 +
years pharmaceutical experience
0 +
years cannabinoid research experience
Legacy of Expertise

Our Team

Innovators Driving the Future of Medicine

At Lupvindol Biosciences, our strength lies in the exceptional talent and expertise of our team. We are a diverse group of professionals, each bringing a wealth of experience and a shared passion for pioneering medical innovations.
Our team is dedicated to transforming the field of pain management with cutting-edge therapies, including innovative combinations of cannabidiol (CBD) and corticosteroids.

HUNTER LAND, PhD

Chief Executive Officer

TIM ROGERS

Chairman

TIM LEFEVER

Vice President
Research & Development

TRINA HAZZAH, DVM, DACVIM

Chief Vetinerary Officer

WILLIAM RAMSEY, DO

Chief Medical Officer

KAREN LOWE

Chief Financial Officer

THOMAS McCABE, JD
General Counsel
Get In Touch

Contact Us

Quick Links

Get Started

  • Resources
  • Guides
  • Examples
  • Docs

Legal

  • Privacy Policy
  • Terms and Conditions

Follow Us

  • Facebook
  • Instagram
  • Twitter

Lupvindol is pioneering an innovative FDA clinical trial program for a fixed-dose combination drug.

Subscribe our newsletter

Copyright © 2025 Lupvindol | Designed By SMCSE Solutions PVT LTD.
Scroll to Top

Hunter Land

Hunter Land, PhD, MS has over 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Most notably, he was GW Pharma’s first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® (FDA-approved prescription CBD) and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), multiple sclerosis, and pain. Dr. Land has presented at over 50 scientific conferences, is a named inventor on nine patent applications, and has over 20 publications. In addition, he serves as a guest lecturer at the University of Wisconsin and the University of Colorado Skaggs School of Pharmacy, and has been featured in Forbes and Entrepreneur as a cannabinoid subject matter expert. Dr. Land also holds several other important positions, including Chief Scientific Officer of the National Hockey League Alumni/NEEKA Brain Health, Board Member at Alterola Biotech, Scientific Advisory Board Member at Nalu Biosciences, Veterinary Cannabis Society, CannMed, and the Council for Federal Cannabis Regulation.

Tim Rogers

Tim Rogers is a highly versatile and accomplished entrepreneur with a career that showcases deep expertise across a variety of industries. His leadership spans complex sectors, and his strategic insight into navigating both emerging and established markets is evident in his success stories, such as the 2024 $58 million NASDAQ reverse merger in the cannabinoid bioscience space.
His ability to transition from pre-IP planning to a fully funded public company on a prestigious exchange is a testament to his deep understanding of financial markets and regulatory landscapes, as well as his skill in scaling businesses rapidly while maintaining robust corporate governance. The cannabinoid bioscience sector, in particular, has unique challenges, and his success in guiding a company through such a significant transition is a remarkable achievement.
Additionally, Tim’s proven success in creating markets, establishing blue-chip partnerships, and guiding companies from concept to manufacturing and distribution underscores his strategic versatility. His ability to convert Intellectual Property into viable commercial opportunities speaks to his capacity to recognize and extract value from innovation, a skill that builds trust among inventors, scientists, and investors.
Tim’s commitment to mentoring young talent and his emphasis on building strong management teams shows his forward-thinking leadership style. By investing in people, he not only contributes to the success of his ventures but also helps nurture the next generation of entrepreneurial leaders.

Tim lefever

Tim Lefever, MS, is a seasoned Director with over 20 years of expertise in preclinical in vivo research, recognized for his exceptional ability to lead effective research teams. He dedicated nine years at the Research Triangle Institute (RTI), where he managed research projects focusing on structure-activity relationships, abuse liability, pharmacology, and pharmacokinetics of cannabinoids. During his tenure at RTI, Tim successfully designed and executed numerous in vivo studies for federally funded grants (NIH), federal contracts (FDA, DEA), and pharmaceutical/biotech contracts, many under GLP conditions. Following his impactful work at RTI, Tim spent three years at Canopy Growth, working closely with the Chief Medical Officer to develop and implement a product safety program. In this role, he evaluated potential products for safety and efficacy through preclinical in vivo studies. An active member of the International Cannabinoid Research Society (ICRS) since 2013, Tim co-hosted the Carolina Cannabinoid Collaborative meeting in 2017. Over his career, he has authored or co-authored numerous manuscripts and presented his research findings at various scientific conferences. Tim’s extensive experience, particularly in cannabinoid research, and his proven leadership and expert

Dr. Trina Hazzah , DVM, DACVIM

Trina Hazzah was born and raised in Washington DC. She attended Tuskegee University School of Veterinary Medicine where she earned her Doctor of Veterinary Medicine in 2006. She completed her small animal internship at Red Bank Veterinary Hospital in New Jersey and a 3-year residency in medical oncology at the Veterinary Oncology and Hematology Center in Connecticut. She has also completed the requirements to be a Certified Veterinary Chinese Herbalist from the Chi Institute of Traditional Chinese Veterinary Medicine. She developed an interest in cannabis medicine during her quest for finding effective integrative approaches for veterinary cancer patients. Over the past 8 years, she has treated hundreds of patients with cannabis. She has since given numerous lectures to veterinarians educating them on the topic of cannabis medicine, performed cannabis-related research, published peerreviewed articles on cannabis in veterinary medicine, co-authored multiple cannabis-related textbooks, and is the president and co-founder of the Veterinary Cannabis Society, which is the first US-based nonprofit, 501(c)(3) organization building awareness of cannabis as medicine for pets.

William Ramsey

Dr. Will Ramsey is a distinguished orthopedic surgeon specializing in adult reconstructive surgery with a focus on hip, knee, and shoulder preservation. He excels in partial and total joint replacements and complex revision surgeries, leveraging advanced techniques for rapid recovery and outpatient care. His minimally invasive direct anterior approach for total hip replacements notably spares muscle, facilitating faster recovery times. Education and Training: North Carolina State University: Bachelor’s Degrees in Biology and Biochemistry Masters in Physiology: North Carolina State University, concurrent work at the National Institute of Environmental Health Sciences and volunteer EMT service Medical Degree: Via College of Osteopathic Medicine, Blacksburg, VA, graduated with honors Dr. Ramsey further honed his expertise through specialty training in orthopedic surgery at the Philadelphia College of Osteopathic Medicine and subspecialty training in total joint reconstruction under Dr. Randall Peyton at Arthritis and Sports Orthopedics in Northern Virginia. Dr. Ramsey’s commitment to patient-centered care and his proficiency in advanced surgical techniques position him as a leader in orthopedic reconstructive surgery, dedicated to improving patient outcomes through innovation and excellence in medical practice.

Karen Lowe

With over 30 years of experience, Karen Lowe is a Big-4 qualified Chartered Accountant with a notable track record across various sectors, including life sciences, medical products, financial services, and manufacturing. Her career spans industry and practice, showcasing her expertise in financial risk management, corporate governance, and legal compliance. Karen has held significant roles in multinational corporations like DHL Group and Johnson & Johnson, where she implemented robust financial management frameworks for sustainable growth. As the Chief Finance Officer at Oxford Cannabinoid Technologies (LSE), she was instrumental in the company’s successful listing on the Main Market of the London Stock Exchange. Currently, she serves as the fractional CFO for an environmental services start-up, demonstrating her versatility in fostering innovation and growth in emerging industries. Her governance expertise is highlighted by her roles on various boards and audit committees as a nonexecutive director. In addition to her executive experience, Karen has a solid background in consultancy, helping companies prepare for public listings and navigate mergers and acquisitions. Her qualifications as an Accredited Counter Fraud Specialist and memberships in the Institute of Risk Management and the Certified Fraud Examiners underscore her proficiency in mitigating financial risks and safeguarding organizational integrity.

Thomas McCABE

Tom McCabe has an extensive background representing clients in securities- related matters. He has worked on the regulatory side of the securities industry as well as in private practice. He began his career in the Enforcement Division of the New York Stock Exchange and subsequently joined the American Stock Exchange Enforcement division where he held the title of director. For more than 30 years, he has been engaged in private practice and has represented many companies and individuals in SEC, FINRA and other regulatory matters including disciplinary proceedings, arbitrations and litigation. Tom is a graduate of Iona University, University College Dublin and New York Law School.